SecBot SecBot
SECBOTREPLAY Home › Report › ORKA

ORKA · Oruka Therapeutics announced positive Phase 2a trial results for its…

Oruka Therapeutics, Inc. · 8-K filed Apr 27, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 27, 2026 at 08:00 ET

Oruka Therapeutics announced positive Phase 2a trial results for its anti-IL-23 antibody ORKA-001 in psoriasis, showing 63.5% of patients achieved complete skin clearance (PASI 100) at 16 weeks with a favorable safety profile. The data supports potential annual dosing and positions ORKA-001 as a best-in-class therapy in a $30B+ market.

  • 63.5% of ORKA-001-treated patients achieved PASI 100 (complete skin clearance) at Week 16 vs. 4.8% for placebo (p < 0.0001)
  • Favorable safety profile: no serious adverse events in treatment arm, TEAE rate (50.8%) lower than placebo (57.1%)
  • Updated PK data supports potential for annual dosing, with drug concentrations remaining above effective levels for a full year
  • Phase 2b trial (EVERLAST-B) ongoing with data expected in 2027 to support Phase 3 initiation

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access